Michael S Anglesio

Michael S Anglesio

UNVERIFIED PROFILE

Are you Michael S Anglesio?   Register this Author

Register author
Michael S Anglesio

Michael S Anglesio

Publications by authors named "Michael S Anglesio"

Are you Michael S Anglesio?   Register this Author

52Publications

1563Reads

6Profile Views

Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer.

J Cancer Res Clin Oncol 2019 Sep 5;145(9):2251-2259. Epub 2019 Aug 5.

Department of Obstetrics and Gynecology, University of Tuebingen, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00432-019-02986-0DOI Listing
September 2019

A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases.

Mod Pathol 2019 Jun 25. Epub 2019 Jun 25.

Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41379-019-0302-0DOI Listing
June 2019

Molecular Subtype Not Immune Response Drives Outcomes in Endometrial Carcinoma.

Clin Cancer Res 2019 Apr 6;25(8):2537-2548. Epub 2018 Dec 6.

Departments of Gynecology and Obstetrics, and University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-18-3241DOI Listing
April 2019

Nuclear β-catenin and CDX2 expression in ovarian endometrioid carcinoma identify patients with favourable outcome.

Histopathology 2019 Feb;74(3):452-462

Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB, Canada.

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/his.13772
Publisher Site
http://dx.doi.org/10.1111/his.13772DOI Listing
February 2019

HACE1 is a potential tumor suppressor in osteosarcoma.

Cell Death Dis 2019 Jan 8;10(1):21. Epub 2019 Jan 8.

Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/s41419-018-1276-4DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6325116PMC
January 2019

You won't believe this old test … that does cheap single-cell mutation detection.

J Pathol Clin Res 2018 Jul;4(3):149-153

Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/cjp2.108DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6065114PMC
July 2018

Identical TP53 mutations provide evidence that late-recurring tubo-ovarian high-grade serous carcinomas do not represent new peritoneal primaries.

Histopathology 2017 12 22;71(6):1014-1017. Epub 2017 Sep 22.

Department of Pathology, Belfast Health and Social Care Trust, Belfast, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/his.13327DOI Listing
December 2017

Endometriosis-associated Ovarian Cancers.

Clin Obstet Gynecol 2017 12;60(4):711-727

*Department of Obstetrics and Gynaecology, OVCARE, Robert HN Ho Research Centre, Vancouver, British Columbia, Canada †Department of Obstetrics and Gynaecology, BC Women's Centre for Pelvic Pain and Endometriosis, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/GRF.0000000000000320DOI Listing
December 2017

LINE-1 retrotransposon-mediated DNA transductions in endometriosis associated ovarian cancers.

Gynecol Oncol 2017 12 9;147(3):642-647. Epub 2017 Oct 9.

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Molecular Oncology, BC Cancer Agency, Vancouver, BC, Canada. Electronic address:

View Article

Download full-text PDF

Source
https://linkinghub.elsevier.com/retrieve/pii/S00908258173135
Publisher Site
http://dx.doi.org/10.1016/j.ygyno.2017.09.032DOI Listing
December 2017

APELA promotes tumour growth and cell migration in ovarian cancer in a p53-dependent manner.

Gynecol Oncol 2017 12 24;147(3):663-671. Epub 2017 Oct 24.

Terry Fox Laboratory, BC Cancer Agency, Vancouver, British Columbia V5Z 1L3, Canada; Cell and Developmental Biology Program, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada; Department of Medical Genetics, University of British Columbia, Vancouver, British Columbia V6T 1Z4, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2017.10.016DOI Listing
December 2017

Cancer-Associated Mutations in Endometriosis without Cancer.

N Engl J Med 2017 05;376(19):1835-1848

From the Departments of Obstetrics and Gynaecology (M.S.A., C.A., C.W., P.J.Y., D.G.H.) and Pathology and Laboratory Medicine (M.S.A., T.M.N., J. Senz, B.T.-C., C.B.G., D.G.H.), University of British Columbia, the Department of Anatomical Pathology, Vancouver General Hospital (T.M.N., H.M.H., J.H., V.L., B.T.-C., A.W., C.B.G., D.G.H.), the Department of Molecular Oncology, British Columbia Cancer Agency (H.M.H., A.L., V.L., N.B., D.G.H.), and the BC Women's Centre for Pelvic Pain and Endometriosis, BC Women's Hospital and Health Centre (F.W., N.O., C.A., C.W., P.J.Y.) - all in Vancouver, BC, Canada; the Department of Oncology (N.P., C.T., K.W.K., L.D., T.-L.W., B.V., I.-M.S.) and Ludwig Center (N.P., Y.W., J.D.C., M.Z., M.P., W.M., A.M., K.W.K., L.D., B.V.), Sidney Kimmel Comprehensive Cancer Center, the Departments of Pathology (N.P., A.A., M.N., L.D.W., T.-L.W., B.V., I.-M.S.) and Gynecology and Obstetrics (J. Segars, I.-M.S.), Johns Hopkins Medical Institutions, Personal Genome Diagnostics (S.J.), and Johns Hopkins University Howard Hughes Medical Institute (B.V.) - all in Baltimore; the Department of Pathology, Seirei Mikatahara Hospital (A.A., H.O.), and the Department of Tumor Pathology, Hamamatsu University School of Medicine (A.A.), Hamamatsu, and the Department of Molecular Pathology, Hiroshima University School of Medicine, Hiroshima (A.A.) - all in Japan; the Department of Pathology, University Medical Center Utrecht, Utrecht, the Netherlands (M.N.); the Departments of Obstetrics and Gynecology (T.S.) and Pathology (R.A., A.H.), Lenox Hill Hospital-Northwell Health (Hofstra University), New York; and the Department of Pathology, Chang Gung Memorial Hospital and Chang Gung University College of Medicine, Tao-Yuan City, Taiwan (R.-C.W.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1614814DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5555376PMC
May 2017

Differences in MEK inhibitor efficacy in molecularly characterized low-grade serous ovarian cancer cell lines.

Am J Cancer Res 2016 1;6(10):2235-2251. Epub 2016 Oct 1.

Department of Obstetrics & Gynaecology, University of British ColumbiaVancouver, British Columbia, Canada; Department of Surgical Oncology, BC Cancer AgencyVancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5088288PMC
October 2016

Synchronous Endometrial and Ovarian Carcinomas: Evidence of Clonality.

J Natl Cancer Inst 2016 Jun 1;108(6):djv428. Epub 2016 Feb 1.

Department of Pathology and Laboratory Medicine, (MSA, HMH, JS, HLC, ANK, BSS, MKM, CBG, SK, DGH) and Department of Obstetrics and Gynaecology (MSA, DGH), University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, Canada (YKW, AB, RM, DSG, SPS); Department of Women's Health, University Hospital Tuebingen, Tuebingen, Germany (MM, FAT, DW, SB, SK); Division of Anatomic Pathology, Synlab MVZ, Institute of Pathology, Mannheim, Germany (FK); Division of Gynecologic Pathology, Institute of Pathology and Neuropathology, University Hospital Tuebingen, Tuebingen, Germany (AS); Department of Anatomical Pathology, Vancouver General Hospital, Vancouver, Canada (CBG).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/jnci/djv428DOI Listing
June 2016

BAF250a Expression in Atypical Endometriosis and Endometriosis-Associated Ovarian Cancer.

Int J Gynecol Cancer 2016 06;26(5):825-32

Departments of *Obstetrics and Gynecology, and †Pathology and Laboratory Medicine, University of British Columbia, Vancouver, British Columbia, Canada; ‡Faculty of Medicine, Universiteit van Amsterdam, Amsterdam, the Netherlands; §Department of Pathology and Laboratory Medicine, BC Cancer Agency; ∥Genetic Pathology Evaluation Centre, University of British Columbia, Vancouver, British Columbia; ¶Division of Gynecologic Oncology, Princess Margaret Cancer Centre, Toronto, Ontario; and #Hereditary Cancer Program, BC Cancer Agency, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/IGC.0000000000000698DOI Listing
June 2016

Morphologic and Molecular Characteristics of Mixed Epithelial Ovarian Cancers.

Am J Surg Pathol 2015 Nov;39(11):1548-57

*Department of Molecular Oncology §Cancer Control Research, BC Cancer Agency Cancer Research Centre †Department of Pathology and Laboratory Medicine ‡Genetic Pathology Evaluation Centre, Anatomical Pathology at the Vancouver General Hospital ‡‡Department of Gynecology and Obstetrics, Division of Gynecologic Oncology, University of British Columbia, Vancouver, BC, Canada ∥Department of Internal Medicine, University of New Mexico, Albuquerque, NM §§Department of Pathology and Laboratory Medicine, University of Calgary, Calgary, AB ¶The Leeds Teaching Hospitals NHS Trust, Leeds #Barts Health NHS Trust, London, United Kingdom **Institut für Pathologie, Referenzzentrum für Gynäkopathologie, Mannheim ††Gynecologic Oncology Center, Kiel ∥∥Department of Gynecology and Obstetrics, Tuebingen University Women's Hospital, Tuebingen, Germany.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1097/PAS.0000000000000476DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4604016PMC
November 2015

Recurrent DICER1 hotspot mutations in endometrial tumours and their impact on microRNA biogenesis.

J Pathol 2015 Oct 6;237(2):215-25. Epub 2015 Jul 6.

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.4569DOI Listing
October 2015

The oncogenic roles of DICER1 RNase IIIb domain mutations in ovarian Sertoli-Leydig cell tumors.

Neoplasia 2015 Aug;17(8):650-60

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, BC, Canada; Department of Molecular Oncology, British Columbia Cancer Agency Cancer Research Centre, Vancouver, BC, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neo.2015.08.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4674484PMC
August 2015

Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.

Mol Cancer Ther 2015 Jun 7;14(6):1495-503. Epub 2015 Apr 7.

Cancer Genetics Laboratory, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia. Department of Pathology, The University of Melbourne, Parkville, Victoria, Australia. Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1535-7163.MCT-15-0039DOI Listing
June 2015

Genomic classification of serous ovarian cancer with adjacent borderline differentiates RAS pathway and TP53-mutant tumors and identifies NRAS as an oncogenic driver.

Clin Cancer Res 2014 Dec 14;20(24):6618-30. Epub 2014 Oct 14.

Department of Gynaecological Oncology, Westmead Hospital, Sydney, New South Wales, Australia. Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, New South Wales, Australia. University of Sydney, Westmead Hospital, Sydney, New South Wales, Australia. Westmead Institute for Cancer Research, Westmead Millennium Institute, Westmead Hospital, Sydney, New South Wales, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-14-1292DOI Listing
December 2014

Harnessing the potential of lipid-based nanomedicines for type-specific ovarian cancer treatments.

Nanomedicine (Lond) 2014 Mar;9(3):501-22

Experimental Therapeutics, British Columbia Cancer Agency Cancer Research Centre, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/nnm.13.220DOI Listing
March 2014

Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study.

Lancet Oncol 2013 Aug 9;14(9):853-62. Epub 2013 Jul 9.

Division of Epidemiology, Department of Health Research and Policy, Stanford University, Stanford, CA, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/S1470-2045(13)70253-5DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4006367PMC
August 2013

FOXL2 molecular testing in ovarian neoplasms: diagnostic approach and procedural guidelines.

Mod Pathol 2013 Jun 25;26(6):860-7. Epub 2013 Jan 25.

Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/modpathol.2012.226DOI Listing
June 2013

Cytokine gene expression signature in ovarian clear cell carcinoma.

Int J Oncol 2012 Sep 26;41(3):1094-100. Epub 2012 Jun 26.

Department of Obstetrics and Gynecology, The Jikei University School of Medicine, Tokyo, Japan.

View Article

Download full-text PDF

Source
https://www.spandidos-publications.com/10.3892/ijo.2012.1533
Publisher Site
http://dx.doi.org/10.3892/ijo.2012.1533DOI Listing
September 2012

Copy number aberrations in benign serous ovarian tumors: a case for reclassification?

Clin Cancer Res 2011 Dec 5;17(23):7273-82. Epub 2011 Oct 5.

Centre for Cancer Genomics and Predictive Medicine, Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1158/1078-0432.CCR-11-2080DOI Listing
December 2011

Clear cell carcinoma of the ovary: a report from the first Ovarian Clear Cell Symposium, June 24th, 2010.

Gynecol Oncol 2011 May 26;121(2):407-15. Epub 2011 Jan 26.

Department of Pathology, University of British Columbia, Vancouver, British Columbia, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ygyno.2011.01.005DOI Listing
May 2011

Subtype-specific mutation of PPP2R1A in endometrial and ovarian carcinomas.

J Pathol 2011 Apr 7;223(5):567-73. Epub 2011 Mar 7.

Department of Pathology and Laboratory Medicine, University of British Columbia, British Columbia Cancer Agency, 3427-600 West 10th Avenue, Vancouver, BC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/path.2848DOI Listing
April 2011

Are there any more ovarian tumor suppressor genes? A new perspective using ultra high-resolution copy number and loss of heterozygosity analysis.

Genes Chromosomes Cancer 2009 Oct;48(10):931-42

VBCRC Cancer Genetics Laboratory, Research Division, Peter MacCallum Cancer Centre, East Melbourne, Victoria, Australia.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/gcc.20694DOI Listing
October 2009

The E3 ligase HACE1 is a critical chromosome 6q21 tumor suppressor involved in multiple cancers.

Nat Med 2007 Sep 12;13(9):1060-9. Epub 2007 Aug 12.

Institute of Molecular Biotechnology of the Austrian Academy of Sciences, Dr. Bohrgasse 3, 1030 Vienna, Austria.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/nm1621DOI Listing
September 2007

Akt-mediated YB-1 phosphorylation activates translation of silent mRNA species.

Mol Cell Biol 2006 Jan;26(1):277-92

Department of Pathology, British Columbia Research Institute for Children's and Women's Health, Vancouver, BC, Canada V5Z 163.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1128/MCB.26.1.277-292.2006DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1317623PMC
January 2006

Differential expression of a novel ankyrin containing E3 ubiquitin-protein ligase, Hace1, in sporadic Wilms' tumor versus normal kidney.

Hum Mol Genet 2004 Sep 14;13(18):2061-74. Epub 2004 Jul 14.

Department of Pathology, British Columbia Research Institute for Children's and Women's Health, University of British Columbia, Vancouver, BC, V5Z 4H4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1093/hmg/ddh215DOI Listing
September 2004